Top Growth Trends in the Subcutaneous Immunoglobulin (SCIG) Market: Key Insights and Opportunities for 2025-2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What key factors are powering the surge in the subcutaneous immunoglobulin (scig) market right now?
There has been notable expansion in the size of the Subcutaneous Immunoglobulin (SCIG) market in the past few years. The market is projected to escalate from a valuation of $12.72 billion in 2024 to approximately $14.52 billion in 2025, representing a Compound Annual Growth Rate (CAGR) of 14.1%. Factors attributable to this historic growth include heightened incidence of immunodeficiency disorders, increased patient inclination towards home-based care, improved therapeutic efficacy, amplification in awareness and diagnostic rates, as well as the strengthening of beneficial reimbursement policies.
How fast Is the subcutaneous immunoglobulin (scig) market expected to grow, and what’s its future value?
The subcutaneous immunoglobulin (SCIG) market size is expected to see rapid growth in the next few years. It will grow to $24.29 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to the growing prevalence of neurological disorders, increasing prevalence of autoimmune diseases, rising awareness and acceptance of immunoglobulin therapy, expanding applications in neurology and dermatology, expansion of healthcare facilities. Major trends in the forecast period include advancements in drug delivery systems, increasing demand for home infusion therapies, developments in antibody therapy, Innovations in formulations, and Innovations in SCIG.
Get your subcutaneous immunoglobulin (scig) market report here!
What are the leading drivers of growth in the subcutaneous immunoglobulin (scig) market?
The growth of the subcutaneous immunoglobulin market is anticipated to be driven by an increased prevalence of secondary immunodeficiency diseases. These diseases are characterized by a diminished or impaired immune system caused not by the immune system itself, but by external factors. This prevalence is fuelled by various factors including aging populations, immunosuppressive treatments, and environmental toxins. Subcutaneous immunoglobulin therapy helps bolster a compromised immune system, particularly in chronic conditions like HIV or autoimmune diseases, thereby preventing infections and bolstering immunological function during treatment. For instance, the UK Health Security Agency noted in October 2023, that there were 3,805 new HIV diagnoses in England in 2022, marking a 22% increase from the preceding year. Therefore, a rise in the prevalence of secondary immunodeficiency diseases is positively impacting the subcutaneous immunoglobulin market’s growth.
Subcutaneous Immunoglobulin (SCIG) Market Driver: Surge in Neurological Disorders Spurs Growth in the Subcutaneous Immunoglobulin Market
What are the key segments defining the subcutaneous immunoglobulin (scig) market?
The subcutaneous immunoglobulin (SCIG) market covered in this report is segmented –
1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)
2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications
3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses
Subsegments:
1) By Immunoglobulin A (IgA): IgA1, IgA2
2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4
3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp
Who are the key firms paving the way for growth in the subcutaneous immunoglobulin (scig) market?
Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy’s Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc., Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc
What emerging trends are influencing the growth of the subcutaneous immunoglobulin (scig) market?
Leading firms in the subcutaneous immunoglobulin market are creating subcutaneous human-klhw, a distinct compound comprising human immune globulins (Ig) that bolsters the immune defenses. This product, intended for subcutaneous application, is aimed at addressing primary immunodeficiency ailments in humans. For example, Grifols S.A., a pharmaceutical company based in Spain, unleashed XEMBIFY 20% subcutaneous immunoglobulin (SCIG) in March 2022. This product is solely designed for treating primary immunodeficiency, thus fulfilling a major medical requirement for individuals who have compromised immune systems. XEMBIFY is a readily available formulation making the treatment protocol simpler and enhancing patient comfort. It remains stable at room temperature for a period of up to 24 months thereby eliminating the requirement for refrigeration during storage and transit, proving exceedingly beneficial in numerous healthcare scenarios.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15935
Which geographic areas are influencing the growth of the subcutaneous immunoglobulin (scig) market?
North America was the largest region in the subcutaneous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Immunoglobulins Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report
PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2024
Immune Health Supplements Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/immune-health-supplements-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
